Canada’s Drug Agency (CDA-AMC) recommends that Talzenna in combination with enzalutamide should be reimbursed by public drug plans for the first-line treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) if certain conditions are met.
